Ergoben

Quick links to important sections

Ergoben

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ergoben

Quick Facts

Property Description
Active Ingredients Ergotamine, Caffeine, Diphenhydramine
Form Oral dosage form (Tablet, Capsule), Suppository
Pharmacological Class Antimigraine Agent, Ergot Alkaloid Combination
Common Use Acute termination of severe vascular headaches
Rx Status Prescription-only (Rx)

Ergoben is a prescription-only, fixed-dose combination medication designed for the acute management of severe vascular headaches. It is officially classified by the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) system under the category of Antimigraine Agents, specifically grouping with Ergot Alkaloids. This targeted classification confirms its specific utility in treating attacks of migraine and cluster headache.

Ergoben: Definition and Pharmacological Class

The core identity of Ergoben is defined by its function as an abortive therapy intended to halt the progression of an intense headache episode. It belongs to the pharmacological class of Ergot Alkaloid Combinations, with Ergotamine acting as the primary vasoconstrictive agent. This strategic approach is clinically recognized for addressing headaches that have not adequately responded to non-specific treatments, serving as a dedicated intervention against the underlying vascular mechanism.

Composition and Origin of Active Ingredients

The unique triple-component formulation includes Ergotamine, the semi-synthetic Ergot Alkaloid vasoconstrictor; Caffeine, a Central Nervous System (CNS) Stimulant; and Diphenhydramine, a Histamine H1 Antagonist. The inclusion of Caffeine is a critical differentiating feature, as it enhances the therapeutic effectiveness of Ergotamine by promoting both its absorption and its primary vasoconstrictive action. This potentiation strategy aims to maximize the drug's impact on the acute event. Ergoben is commonly supplied in solid oral dosage forms (tablet, capsule) and is also formulated for rectal administration as a suppository.

What side effects are possible with Ergoben?

Possible Side Effects and Safety Information

The official safety profile for Ergoben, which contains ergotamine and caffeine, is structured around high-level safety constraints and classifications of adverse reactions as documented in government regulatory sources.

Frequency-Classified Adverse Reactions

The most commonly classified side effects include nausea, vomiting, and dizziness. Uncommon reactions documented in regulatory safety reports often involve the nervous system, such as paresthesia (tingling or numbness) and hypoesthesia, as well as gastrointestinal effects like diarrhea and abdominal pain.

Serious Adverse Reactions and Key Constraints

Ergoben's safety profile includes a documented risk of serious vascular adverse events. The condition known as Ergotism is listed as a serious adverse reaction, characterized by intense peripheral vasoconstriction that can lead to signs of peripheral vascular ischemia. Rare reports also describe Myocardial Ischemia and the development of fibrotic changes (e.g., cardiac valve or retroperitoneal fibrosis) associated with long-term, uninterrupted use.

The medication is contraindicated in several specific populations and conditions. It should not be used in individuals with severe hepatic or renal impairment or in those with pre-existing vascular conditions like uncontrolled hypertension or coronary artery disease. Furthermore, its use is contraindicated during pregnancy and lactation. Prolonged, continuous administration is also associated with the development of Medication Overuse Headache, a rebound effect upon discontinuation.

Overdose and Emergency Response

The official regulatory guidance for Ergoben overdosage mandates that individuals seek immediate medical attention and contact a Poison Control Center right away if an overdosage is suspected. Overdosage is classified as a severe event due to the potential for life-threatening outcomes, including shock and peripheral vascular ischemia.

The toxic effects of an acute overdosage are primarily attributed to the ergotamine component, leading to a severe condition known as ergotism. This syndrome is defined by intense arterial vasoconstriction which can result in peripheral vascular ischemia and, if untreated, the progression to gangrene.

Documented clinical manifestations of overdose include a range of systemic and cardiovascular signs such as vomiting, hypertension or hypotension, slow or fast heartbeat, and diminished or absent peripheral pulses. Neurological findings may involve drowsiness, stupor, convulsions, or coma. The extremities commonly exhibit signs like numbness, tingling, or pain, as well as cyanosis (bluish discoloration).

Official management of overdosage is classified as symptomatic and supportive, consistent with the documented finding that no specific antidote is known. Immediate medical support and stabilization are required to manage these manifestations.

Therapeutic Uses of Ergoben

What Ergoben Treats: Main Uses and Benefits

Ergoben is commonly used to help with acute episodes of intense, vascular headache episodes, a category that includes migraine and histaminic cephalalgia (cluster headaches). The combination is considered relevant for managing symptoms associated with acute or disruptive episodes of vascular headache. This medication provides targeted symptomatic support, especially when symptoms become more noticeable and short-term symptomatic assistance is considered relevant.

The primary therapeutic goal is to provide support that may assist with managing the severity and duration of the episode. It is applied when appropriate when the high intensity of the headache may be associated with episodes that have not responded to non-specific analgesic treatments. This supportive relief contributes to easing the overall symptom load and may assist with maintaining a sense of stability when symptoms interfere with routine activities.

Quick Fact: Support for Acute Symptomatic Episodes

“The medication is commonly used across conditions presenting with acute episodes marked by increased discomfort.”

Regulatory References

  1. official NIH DailyMed labeling

Eligibility and Restrictions for Use

Who Can and Cannot Use Ergoben

Ergoben is officially designated for the acute treatment of severe vascular headaches in the adult population. The regulatory labeling establishes explicit contraindications defining who must not use this medicine.

Use of Ergoben is formally contraindicated for patients with serious underlying vascular conditions, including Ischemic Heart Disease, Peripheral Vascular Disease, and uncontrolled hypertension. It is also prohibited in patients experiencing severe hepatic or renal impairment or severe infectious states (Sepsis). Individuals with a known hypersensitivity to ergotamine, caffeine, or any ergot alkaloid derivative must not use this medicine. Specific migraine presentations, such as Hemiplegic or Basilar Migraine, are also contraindications.

Regarding age and life stage, the medicine is contraindicated during pregnancy and breastfeeding. Furthermore, use is not recommended for the pediatric population (younger than 12 years) or the geriatric population (older than 65 years). The drug is intended only for acute, intermittent use and is restricted from chronic daily administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ergoben is structured around pharmacokinetic changes involving metabolic enzymes and transporters, as well as pharmacodynamic effects on the heart and vasculature.

Interacting Product Category Regulatory Constraint or Implication
Strong CYP3A4/P-gp Inhibitors Co-administration is generally contraindicated due to a severe risk of increased Ergoben exposure. This can lead to serious toxicity, including profound peripheral vasospasm (ergotism).
Strong CYP3A4 Inducers Concomitant use should typically be avoided as these agents may significantly reduce the exposure and effectiveness of Ergoben.
Drugs Affecting Cardiac Repolarization (QT Prolonging) Co-administration is restricted due to a pharmacodynamic risk of increased and potentially life-threatening cardiac arrhythmias (Torsades de Pointes).
Acid-Reducing Agents Specific timing requirements are mandated to ensure appropriate drug absorption, as agents that raise gastric pH can impair the bioavailability of Ergoben.
Other Ergot Derivatives Co-administration is restricted due to the potential for cumulative toxicity, which can lead to severe vascular events.

Regulatory documents explicitly list specific interacting agents, such as Dihydroergotamine, Ergotamine, and Methylergonovine, along with strong CYP3A4 inhibitors (e.g., specific HIV protease inhibitors), as being either contraindicated or requiring significant clinical management. Population-specific cautions are noted for patients with pre-existing cardiac conduction abnormalities or electrolyte imbalances (e.g., hypokalemia/hypomagnesemia) who are at increased risk of pharmacodynamic interactions.

Mechanism of Action

Selective Constriction of Cranial Vasculature

This core mechanism involves Ergotamine acting as a partial agonist at specific serotonin 5-HT1B receptors on the smooth muscle cells of extracranial and dural blood vessels. This receptor engagement triggers immediate vascular smooth muscle contraction, inducing a rapid reduction in vessel diameter. The mechanism is complemented by Caffeine's antagonism of adenosine receptors, which independently results in a reduction of cerebral blood flow, promoting an additive vasoconstrictive action.


Inhibition of Neurogenic Signaling

Beyond its vascular action, Ergotamine also engages a second key mechanism by activating 5-HT1D receptors located on peripheral sensory nerve endings (trigeminal system). This binding acts pre-synaptically to inhibit the release of pro-inflammatory neuropeptides, such as CGRP. This action modifies the early molecular steps that regulate pathway signaling.


Central Nervous System Modulation and Potentiation

The final mechanistic domain involves complementary actions. Caffeine provides a mechanistic potentiation by enhancing the rate of Ergotamine absorption from the gut. Furthermore, Diphenhydramine exerts a central depressant effect by acting as an antagonist at H1 histamine receptors. This specific CNS modulation results in generalized central nervous system sedation.

Dosage and Administration Information

The administration of Ergoben (ergotamine/caffeine) is defined as a time-and-dose-limited intervention for acute episodes. It is not for chronic daily administration and should be initiated at the first sign of an attack to maximize intended use.


Official Administration Guidelines

Usage Rule Oral Tablet (1 mg Ergotamine / 100 mg Caffeine) Rectal Suppository (2 mg Ergotamine / 100 mg Caffeine)
Route of Administration Oral Rectal
Initial Dose at Onset 2 tablets (2 mg Ergotamine) 1 suppository (2 mg Ergotamine)
Subsequent Dosing 1 tablet every 30 minutes, if required for relief. May repeat once after 1 hour if relief is needed.
Maximum Dose per Attack 6 tablets (6 mg Ergotamine) 2 suppositories (4 mg Ergotamine)
Maximum Weekly Dose 10 tablets (10 mg Ergotamine) total during any 7-day period. 5 suppositories (10 mg Ergotamine) total during any 7-day period.

Procedural and Population Constraints

The oral tablets may be taken with or without food. For the rectal form, the suppository should be chilled in ice-cold water to ensure firmness before unwrapping and insertion.

The safety and effectiveness of this combination have not been established for pediatric patients. Furthermore, its use is guided by strict weekly maximums that must not be exceeded, confirming the drug's role as an acute, intermittent treatment and preventing its application in a continuous manner.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ergoben

This section provides a factual, non-advisory summary of the clinical research landscape for ergotamine/caffeine combinations. It focuses on the types of studies conducted, the populations examined, and the recognized scope and limitations of the evidence base. This information is intended to help contextualize what has been observed in research settings.


Evidence for Use in Acute Migraine Episodes

The evidence base for the acute management of migraine episodes primarily includes findings from Randomized Controlled Trials (RCTs) and Crossover Trials. These studies were used in research exploring how symptoms change over time, often comparing the combination against a placebo. The study designs focused on adults experiencing conditions characterized by acute or disruptive episodes of moderate to severe pain.

Research examined outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort. Studies monitored whether headache pain severity changed or entirely resolved, and tracked how symptoms evolved over a short period (typically 24 to 48 hours). The findings describe patterns observed in the studies related to symptom patterns and the state of being pain-free, as well as recurrence rates.

Evidence for Use in Acute Cluster Headaches

Research examining this medication for acute cluster headaches includes a smaller volume of dedicated studies, including both controlled and crossover trials. These studies were applied in research contexts involving fluctuating or unstable symptoms. The trials explored short-term symptom changes, with researchers measuring outcomes related to changes in episodic symptom activity or pain severity scores.

What is Still Uncertain About Ergoben

The primary focus of the existing research is on short-term symptom patterns associated with a single acute episode; therefore, long-term outcomes are not well characterized. Data for special populations, such as older adults or children/adolescents, remain insufficient. Comparative evidence is lacking in large-scale studies against some newer treatments, and because many of the key studies were conducted several decades ago, evidence quality varies across studies.

Key Studies & References

  1. NIH DailyMed Labeling: Ergotamine Tartrate and Caffeine Suppositories
  2. NICE Guideline CG150: Headaches in over 12s - Diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Ergoben (FAQ)

Q: Will taking Ergoben affect my ability to drive or operate machinery?

Official information states that adverse reactions such as dizziness, vertigo, and drowsiness are reported when using this medication. Because the medicine contains components that cause central nervous system sedation, these effects may impact the capacity to safely drive or operate heavy machinery. Patients are cautioned to be aware of how the medicine affects them before engaging in these activities.

Q: Are there any studies looking at Ergoben use in pregnant women? (Informational only)

Official regulatory warnings indicate that this medicine is contraindicated in pregnancy because it may cause fetal harm. Due to this severe safety warning, studies evaluating the medicine's effectiveness or safety in this population are generally not performed.

Q: If I stop taking Ergoben suddenly, will I have withdrawal symptoms?

Regulatory documents state that in rare instances, patients who have used the medicine indiscriminately or for long periods may experience withdrawal symptoms upon stopping it. These symptoms most often consist of a rebound headache upon discontinuation.

Q: Does Ergoben affect sleep patterns?

Official product information lists drowsiness (somnolence) as a reported side effect of the medicine. This is due to one of the active components, which is known to cause a general depressant effect on the central nervous system, and may therefore affect alertness and sleep patterns.

Q: Does Ergoben interact with caffeine or energy drinks?

The medicine itself is a combination product that includes caffeine to enhance its effect and absorption. Using external caffeine sources, such as energy drinks, in combination with this medicine is generally associated with a higher risk because the drug also has a vasoconstrictive action that could be intensified.

Q: Does the dose of Ergoben need to be adjusted based on weight or age?

The regulatory dosing guidelines are based on the need for acute headache management, not on body weight. However, the official documents state that the medicine is not recommended for the geriatric population (older adults) and its safety has not been established for pediatric patients (children and teenagers).

Q: Is there a risk of overdose with Ergoben? (Factual/Informational)

Yes, there is a defined risk of overdose if the maximum recommended doses are exceeded. Regulatory documents clearly define the maximum number of doses allowed per attack and per week. Exceeding these limits can lead to serious toxicity, including intense peripheral vasoconstriction known as Ergotism.

Q: What if I forget to take my dose of Ergoben?

For this acute-use medicine, regulatory guidance addresses the procedure for a missed dose, stating the goal is to avoid exceeding the maximum dose. Regulatory instructions caution patients not to take a double dose and generally direct patients to skip the missed dose if it is almost time for the next scheduled dose.

Q: Is Ergoben known to interact with birth control pills?

Regulatory documents have noted a potential interaction where certain medications, such as oral contraceptives, may increase the concentration of caffeine in the blood. Since caffeine is an active ingredient in Ergoben, this may affect your overall exposure to the drug's components.

Q: How long does the effect of one dose of Ergoben typically last?

Official regulatory information provides the pharmacokinetic data for the medicine, stating that the plasma elimination half-life is approximately 3.5 hours. The half-life describes the time it takes for the amount of drug in the body to be reduced by half.

Q: Are there any specific foods I should avoid while on Ergoben?

Yes, official patient information contains a strong warning against the consumption of grapefruit or grapefruit juice while using this medicine. This is because grapefruit may interfere with the metabolism of the drug, which can lead to increased blood levels of the active ingredients and potentially raise the risk of side effects.

Q: Does Ergoben interact with commonly used supplements like vitamins or herbal products?

Official regulatory guidelines advise patients to inform their healthcare professional of all concomitant medications and products, including vitamins and herbal supplements, due to the potential for interactions.

Q: Is Ergoben known to be addictive or habit-forming?

Yes. Official patient safety information indicates that if the medicine is taken too frequently or for prolonged periods, it may become habit-forming. This pattern of use is associated with the serious unwanted effect known as Medication Overuse Headache (rebound headache).

Q: What should I do if I suspect an interaction between Ergoben and another drug?

Regulatory guidance describes the necessity for patients to report to their physician immediately any symptoms of a serious side effect, such as tingling, numbness, or chest pain. The use of any new medicine, prescription or over-the-counter, requires discussion with a physician before it is started.

Q: Are there any warnings about taking Ergoben before surgery?

Regulatory warnings emphasize the importance of informing the surgical team that this medicine is being taken before any procedure. This is because the medicine acts as a vasoconstrictor (it narrows blood vessels), and some perioperative guidelines detail the necessity of temporarily stopping the medication prior to surgery to reduce the risk of complications.

Q: What happens if I accidentally take two doses of Ergoben at once?

The maximum dose allowed for a single attack is explicitly defined in regulatory documents. Accidentally taking two doses at once may exceed the safe initial dose and immediately increases your risk of side effects and serious toxicity, such as Ergotism. Such an event requires immediate professional medical management due to the serious risks involved.

Q: Can men and women use Ergoben in the same way?

For adult patients who are not pregnant or breastfeeding, the official dosing and use guidelines are the same for both men and women. The only sex-specific restrictions are the strict contraindications for pregnant and breastfeeding women due to the risk of fetal harm and effects on the infant.

Q: What happens if Ergoben is taken past its expiration date?

Regulatory guidelines establish that the drug must retain its strength and quality until the marked expiration date. Taking medicine after this date is not recommended because it may lose effectiveness or, in rare cases, degrade into potentially toxic compounds.

Q: Does smoking affect how well Ergoben works?

Yes. Regulatory documents specifically warn that Nicotine, which is found in tobacco products and smoking, may provoke vasoconstriction (blood vessel narrowing) in some patients. This increases the risk of an ischemic (blood flow restriction) response when combined with this medicine.

How should Ergoben be stored and disposed of?

Storage and Handling Requirements

Ergoben (oral tablets) must be stored at Controlled Room Temperature (CRT), specifically 20^circ to 25 C (68^circ to 77 F), with temporary excursions permitted between 15^circ and 30 C. Official labeling requires the medication to be protected from light, heat, and moisture, and it must not be allowed to freeze.

Storage Classification Mandatory Conditions
Temperature Controlled Room Temperature (20^circ to 25 C)
Protection Protect from light, heat, and moisture; Do not freeze
Container Keep in original container, tightly closed

Disposal Instructions

To ensure safety, the product must be stored out of the sight and reach of children. Unused or outdated medicine must be disposed of safely and promptly. The recommended method for disposal is through an official drug take-back program. If a take-back program is unavailable, disposal may be done via household trash after mixing the medicine with an undesirable substance (e.g., dirt, used coffee grounds) and sealing it in a container. The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ergoben found in:

A-Z Index: